Edwards Lifesciences Corporation (EW)
NYSE: EW · Real-Time Price · USD
92.01
-2.43 (-2.57%)
Oct 30, 2026, 4:00 PM EDT - Market closed
Edwards Lifesciences Revenue
Edwards Lifesciences had revenue of $1.74B in the quarter ending June 30, 2026, with 13.63% growth. This brings the company's total for the last twelve months to $6.51B, up 14.55% year-over-year. In the year 2025, Edwards Lifesciences had annual revenue of $6.07B with 11.55% growth. That makes Edwards Lifesciences the 2,147th largest company in the world by revenue and 632nd in the United States.
Revenue (ttm)
$6.51B
Revenue Growth
+14.55%
P/S Ratio
8.14
Revenue / Employee
$407,019
Employees
16,000
Market Cap
53.03B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Edwards Lifesciences breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.07B | 628.10M | 11.55% |
| Dec 31, 2024 | 5.44B | 429.50M | 8.57% |
| Dec 31, 2023 | 5.01B | 546.00M | 12.23% |
| Dec 31, 2022 | 4.46B | -768.50M | -14.69% |
| Dec 31, 2021 | 5.23B | 846.20M | 19.29% |
| Dec 31, 2020 | 4.39B | 38.30M | 0.88% |
| Dec 31, 2019 | 4.35B | 625.20M | 16.79% |
| Dec 31, 2018 | 3.72B | 287.50M | 8.37% |
| Dec 31, 2017 | 3.44B | 471.60M | 15.91% |
| Dec 31, 2016 | 2.96B | 470.00M | 18.85% |
| Dec 31, 2015 | 2.49B | 170.80M | 7.35% |
| Dec 31, 2014 | 2.32B | 277.40M | 13.56% |
| Dec 31, 2013 | 2.05B | 145.90M | 7.68% |
| Dec 31, 2012 | 1.90B | 221.00M | 13.17% |
| Dec 31, 2011 | 1.68B | 231.60M | 16.01% |
| Dec 31, 2010 | 1.45B | 125.60M | 9.51% |
| Dec 31, 2009 | 1.32B | 83.70M | 6.76% |
| Dec 31, 2008 | 1.24B | 146.60M | 13.44% |
| Dec 31, 2007 | 1.09B | 54.10M | 5.22% |
| Dec 31, 2006 | 1.04B | 39.10M | 3.92% |
| Dec 31, 2005 | 997.90M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Abbott Laboratories | 48.23B |
| Medtronic | 37.54B |
| Stryker | 25.84B |
| GE HealthCare Technologies | 21.64B |
| Boston Scientific | 21.07B |
| Koninklijke Philips | 20.18B |
| Zimmer Biomet Holdings | 8.51B |
| Smith & Nephew | 6.30B |
EW News
- 8 days ago - Edwards Lifesciences added to ‘Core Ideas’ list at Evercore, Illumina removed - TheFly
- 10 days ago - 7 healthcare stocks that stand out as investors pay up for the sector - Market Watch
- 10 days ago - Edwards Lifesciences announces U.S. FDA approval of PASCAL Precision - TheFly
- 10 days ago - FDA Approval of Edwards Lifesciences' PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease - Business Wire
- 24 days ago - Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026 - Business Wire
- 25 days ago - Edwards Lifesciences initiated with an Overweight at Barclays - TheFly
- 26 days ago - Citi opens ‘upside 90-day catalyst watch’ on Edwards Lifesciences - TheFly
- 26 days ago - Edwards Lifesciences to Host Investor Event in Conjunction With TCT - Business Wire